Transurethral resection of the prostate using intrathecal dexmedetomidine with variables doses of bupivacaine
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 7, Pages 3215-3219
AbstractBackground: Benign prostatic hyperplasia (BPH) is the most frequent cause of lower urinary tract symptoms (LUTS) in the aging male. The present study compared intrathecal dexmedetomidine with low-dose bupivacaine spinal anaesthesia versus a higher dose of bupivacaine in patients undergoing transurethral resection of the prostate (TURP).
Materials & Methods: 60 male patients undergoing transurethral resection of the prostatewere divided into 2 groups of 30 each. Group I received 7.5 mg of 0.5% hyperbaric bupivacaine hydrochloride and group II received 3 µg of dexmedetomidine hydrochloride along with 6 mg of 0.5% hyperbaric bupivacaine hydrochloride. Parameters such as regression time from peak sensory block level, assessment of the motor block scales, haemodynamic alterations were recorded.
Results: Time to reach T10 sensory block was 12.6 minutes in group I and 10.2 minutes in group II. Modified Bromage score at the end of surgery 1 was seen in 7 in group I, 2 in 8 in group I and 17 in group II, 3 seen 15 in group I and 13 in group II. VAS score at 1 hours was 3.4 and 2.6, at 2 hours was 2.1 and 2.0, at 3 hours was 1.9 and 1.5 and at 4 hours was 1.1 and 1.3. The difference was significant (P< 0.05). Common side effects werenausea seen in 4 in group I and 3 in group II, vomiting 3 in group I and 2 in group II, pruritis 3 in group I and 1 in group II and hypotension 1 in group I and 2 in group II.
Conclusion: Authors found that addition of 3 µg of dexmedetomidine added to 6 mg bupivacaine resulted prolonged perioperative analgesia and a faster onset and longer duration of sensory and motor block.
- Article View: 6
- PDF Download: 15